HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering?

Herz

Volumn 25, Issue 2, 2000, Pages 117-125

  März, Winfried ^a   Wieland, Heinrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atherosclerosis; Cholesterol; Coronary artery disease; HMG CoA reductase inhibitor; Inflammation

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; MACROPHAGE ACTIVATION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

EID: 0034010730     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00001949     Document Type: Review

References (48)

1. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and naegatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;111:1223-30.
2. Bellosta S, Via D, Canavesi M, Pfister P, et al. HMG-CoA reductase inhibitors reduce MMP-g secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
3. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isprenoid synthesis and cell growth. J Lipid Res 1980;21:505-17.
4. Brown MS, Goldstein JL, Krieger M, Ho YK, Anderson RGW. Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J Cell Biol 1979;82:597-613.
5. Chakrabarti R, Engleman EG. Interrelationships between mevlonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991;266:12216-22.
6. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. Arterioscler Thromb Vasc Biol 1997;17:265-72.
7. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989;11:863-69.
8. Cutts JL, Bankhurst AD. Reversal of Lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990;139:244-52.
9. Cutts JL, Scallen TJ, Watson J, et al. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139:550-7.
10. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279: 1477-82.
11. Downs JR, Clearfield M, Weis S, et al., Group for the AFCAPS/Tex-CAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
12. Drake TA, Hannani K, Fei H, et al. Minimally oxidized LDL induces tissue fatcor expression in cultured endothelial cells. Am J Pathol 1991;138:601-8.
13. Galle J, Mülsch A, Busse R, et al. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium derived relaxing factor. Arterioscler Thromb 1991;11:198-203.
14. Geng YJ, Wu Q, Muszynski Mea. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler Thromb Vac Biol 1996;16:19-27.
15. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
16. Goldstein JL, Ho YK, Basu SK, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
17. Grandaliano G, Biswas P, Choudhury GG, et al. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993;44:503-8.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet 1994;344:1383-9.
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
20. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study Group. Circulation 1998;97:1440-5.
21. Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci USA 1982;79:1712-6.
22. Haverkate F, Thompson SG, Pyke SDM, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
23. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996;61:1469-74.
24. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after transplantation. N Engl J Med 1995;333: 621-7.
25. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
26. Kreuzer J, Bader J, Jahn L. Chemotaxis of the monocyte line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991;1991:203-9.
27. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47.
28. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
29. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993;13:439-44.
30. Nakashima Y, Raines EW, Plump AS, et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apo E-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18:842-51.
31. Rajavashith TB, Andalibi AS, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low-den-sity lipoproteins. Nature 1990;344:254-7.
32. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;366:729-32.
33. Ridker PM, Hennekens CH, Riotman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
34. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
35. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
36. Rohde LE, Lee RT, Rivero J, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1765-70.
37. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. JAMA 1998;279:1643-50.
38. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
39. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
40. Shepherd J, Cobbe SM, Ford I, et al., Group ftWoSCPS. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
41. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462-78.
42. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells Involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883-7.
43. Tanner FC, Noll G, Boulanger CM, et al. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium derived nitric oxide. Circulation 1991;183:2012-20.
44. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96:4204-10.
45. Tracy R, Lemaitre R, Psaty B, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
46. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation 1997;96:1398-1402.
47. Williams JK, Sukova CK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.
48. Xu XP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999;99: 993-8.